The CCN proteins: Important signaling mediators in stem cell differentiation and tumorigenesis

Histology and Histopathology

Volumn 25, Issue 6, 2010, Pages 795-806

  Zuo, Guo Wei ^a,b   Kohls, Christopher D ^b,c   He, Bai Cheng ^a,b   Chen, Liang ^a,b   Zhang, Wenli ^a,d   Shi, Qiong ^a,b   Zhang, Bing Qiang ^a,b   Kang, Quan ^a,b   Luo, Jinyong ^a,b   Luo, Xiaoji ^a,b   Wagner, Eric R ^b   Kim, Stephanie H ^b   Restegar, Farbod ^b   Haydon, Rex C ^b   Deng, Zhong Liang ^a,b   Luu, Hue H ^b   He, Tong Chuan ^a,b   Luo, Qing ^a,b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c MIAMI UNIVERSITY   (United States)

^d SICHUAN UNIVERSITY   (China)

Author keywords

CCN family; Chondrogenesis; Osteogenesis; Stem Cell Differentiation; Tumorigenesis

Indexed keywords

CCN PROTEIN;

ANGIOGENESIS; ANIMAL; BONE DEVELOPMENT; CANCER STEM CELL; CELL ADHESION; CELL DIFFERENTIATION; CELL TRANSFORMATION; CHONDROGENESIS; CYTOLOGY; GROWTH, DEVELOPMENT AND AGING; HUMAN; MESENCHYMAL STEM CELL; METABOLISM; MOUSE; MUTATION; NEOPLASM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CCN INTERCELLULAR SIGNALING PROTEINS; CELL ADHESION; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CHONDROGENESIS; GROWTH AND DEVELOPMENT; HUMANS; MESENCHYMAL STEM CELLS; MICE; MUTATION; NEOPLASMS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOGENESIS; SIGNAL TRANSDUCTION;

EID: 77953403597     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Abreu J.G., Ketpura N.I., Reversade B. and De Robertis E.M. (2002). Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat. Cell Biol. 4, 599-604.
2. Babic A.M., Chen C.C. and Lau L.F. (1999). Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol. Cell. Biol. 19, 2958-2966.
3. Babic A.M., Kireeva M.L., Kolesnikova T.V. and Lau L.F. (1998). CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 95, 6355-6360.
4. Baguma-Nibasheka M. and Kablar B. (2008). Pulmonary hypoplasia in the connective tissue growth factor (Ctgf) null mouse. Dev. Dyn. 237, 485-493.
5. Banerjee S., Dhar G., Haque I., Kambhampati S., Mehta S., Sengupta K., Tawfik O., Phillips T.A. and Banerjee S.K. (2008). CCN5/WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells. Cancer Res. 68, 7606-7612.
6. Benini S., Perbal B., Zambelli D., Colombo M.P., Manara M.C., Serra M., Parenza M., Martinez V., Picci P. and Scotlandi K. (2005). In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene 24, 4349-4361.
7. Bennewith K.L., Huang X., Ham C.M., Graves E.E., Erler J.T., Kambham N., Feazell J., Yang G.P., Koong A. and Giaccia A.J. (2009). The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res. 69, 775-784.
8. Bork P. (1993). The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett. 327, 125-130.
9. Bradham D.M., Igarashi A., Potter R.L., Grotendorst G.R. (1991). Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J. Cell Biol. 114, 1285-1294.
10. Brigstock D.R. (1999). The connective tissue growth factor/cysteine-Rich 61/Nephroblastoma Overexpressed (CCN) Family. Endocrine Rev. 20, 189-206.
11. Brigstock D.R., Goldschmeding R., Katsube K.I., Lam S.C., Lau L.F., Lyons K., Naus C., Perbal B., Riser B., Takigawa M. and Yeger H. (2003). Proposal for a unified CCN nomenclature. Mol. Pathol. 56, 127-128.
12. Cervello M., Giannitrapani L., Labbozzetta M., Notarbartolo M., D'Alessandro N., Lampiasi N., Azzolina A. and Montalto G. (2004). Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. Ann. N.Y. Acad. Sci. 1028, 432-439.
13. Chen C.C. and Lau L.F. (2009). Functions and mechanisms of action of CCN matricellular proteins. Int. J. Biochem. Cell Biol. 41, 771-783.
14. Chen C.C., Chen N. and Lau L.F. (2001). The angiogenic factors Cyr61 and connective tissue growth factor induce adhesive signaling in primary human skin fibroblasts. J. Biol. Chem. 276, 10443-10452.
15. Chen P.P., Li W.J., Wang Y., Zhao S., Li D.Y., Feng L.Y., Shi X.L., Koeffler H.P., Tong X.J. and Xie D. (2007). Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One 2, e534.
16. Chiou M.J., Chao T.T., Wu J.L., Kuo C.M. and Chen J.Y. (2006). The physiological role of CTGF/CCN2 in zebrafish notochond development and biological analysis of the proximal promoter region. Biochem. Biophys. Res. Commun. 349, 750-758.
17. Cui R.R., Huang J., Yi L., Xie H., Zhou H.D., Yuan L.Q., Wang M., Peng Y.Q., Luo X.H. and Liao E.Y. (2007). WISP3 suppresses insulin-like growth factor signaling in human chondrocytes. Mol. Cell. Endocrinol. 279, 1-8.
18. Davies S.R., Watkins G., Mansel R.E. and Jiang W.G. (2007). Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer. Ann. Surg. Oncol. 14, 1909-1918.
19. Deng Z.L., Sharff K.A., Tang N., Song W.X., Luo J., Luo X., Chen J., Bennett E., Reid R., Manning D., Xue A., Montag A.G., Luu H.H., Haydon R.C. and He T.C. (2008). Regulation of osteogenic differentiation during skeletal development. Front. Biosci. 13, 2001-2021.
20. Desnoyers L. (2004). Structural basis and therapeutic implication of the interaction of CCN proteins with glycoconjugates. Curr. Pharm. Des. 10, 3913-3928.
21. Dhar G., Mehta S., Banerjee S., Gardner A., McCarty B.M., Mathur S.C., Campbell D.R., Kambhampati S. and Banerjee S.K. (2007a). Loss of WISP-2/CCN5 signaling in human pancreatic cancer: a potential mechanism for epithelial-mesenchymal-transition. Cancer Lett. 254, 63-70.
22. Dhar K., Banerjee S., Dhar G., Sengupta K. and Banerjee S.K. (2007b). Insulin-like growth factor-1 (IGF-1) induces WISP-2/CCN5 via multiple molecular cross-talks and is essential for mitogenic switch by IGF-1 axis in estrogen receptor-positive breast tumor cells. Cancer Res. 67, 1520-1526.
23. Dhar G., Banerjee S., Dhar K., Tawfik O., Mayo M.S., Vanveldhuizen P.J. and Banerjee S.K. (2008). Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2. Cancer Res. 68, 4580-4587.
24. Erwin W.M. (2008). The Notochord, Notochordal cell and CTGF/CCN-2: ongoing activity from development through maturation. J. Cell Commun. Signal. 2, 59-65.
25. French D.M., Kaul R.J., D'Souza A.L., Crowley C.W., Bao M., Frantz G.D., Filvaroff E.H. and Desnoyers L. (2004). WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair. Am. J. Pathol. 165, 855-867.
26. Fritah A., Saucier C., De Wever O., Bracke M., Bieche I., Lidereau R., Gespach C., Drouot S., Redeuilh G. and Sabbah M. (2008). Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol. Cell. Biol. 28, 1114-1123.
27. Gao R. and Brigstock D.R. (2003). Low density lipoprotein receptor-related protein (LRP) is a heparin-dependent adhesion receptor for connective tissue growth factor (CTGF) in rat activated hepatic stellate cells. Hepatol. Res. 27, 214-220.
28. Glukhova L., Angevin E., Lavialle C., Cadot B., Terrier-Lacombe M.J., Perbal B., Bernheim A. and Goguel A.F. (2001). Patterns of specific genomic alterations associated with poor prognosis in high-grade renal cell carcinomas. Cancer Genet. Cytogenet. 130, 105-110.
29. Gray M.R., Malmquist J.A., Sullivan M., Blea M. and Castellot J.J.Jr. (2007). CCN5 Expression in mammals. II. Adult rodent tissues. J. Cell Commun. Signal. 1, 145-158.
30. Gupta N., Wang H., McLeod T.L., Naus C.C., Kyurkchiev S., Advani S., Yu J., Perbal B. and Weichselbaum R.R. (2001). Inhibition of glioma cell growth and tumorigenic potential by CCN3 (NOV). Mol. Pathol. 54, 293-299.
31. Gupta R., Hong D., Iborra F., Sarno S. and Enver T. (2007). NOV (CCN3) functions as a regulator of human hematopoietic stem or progenitor cells. Science 316, 590-593.
32. Hashimoto Y., Shindo-Okada N., Tani M., Nagamachi Y., Takeuchi K., Shiroishi T., Toma H. and Yokota J. (1998). Expression of the Elm1 gene, a novel gene of the CCN (connective tissue growth factor, Cyr61/Cef10, and neuroblastoma overexpressed gene) family, suppresses In vivo tumor growth and metastasis of K-1735 murine melanoma cells. J. Exp. Med. 187, 289-296.
33. Hashimoto Y., Shindo-Okada N., Tani M., Takeuchi K., Toma H. and Yokota J. (1996). Identification of genes differentially expressed in association with metastatic potential of K-1735 murine melanoma by messenger RNA differential display. Cancer Res. 56, 5266-5271.
34. Heath E., Tahri D., Andermarcher E., Schofield P., Fleming S. and Boulter C.A. (2008). Abnormal skeletal and cardiac development, cardiomyopathy, muscle atrophy and cataracts in mice with a targeted disruption of the Nov (Ccn3) gene. BMC. Dev. Biol. 8, 18.
35. Hirschfeld M., zur Hausen A., Bettendorf H., Jager M. and Stickeler E. (2009). Alternative splicing of Cyr61 is regulated by hypoxia and significantly changed in breast cancer. Cancer Res. 69, 2082-2090.
36. Holbourn K.P., Acharya K.R. and Perbal B. (2008). The CCN family of proteins: structure-function relationships. Trends Biochem. Sci. 33, 461-473.
37. Holloway S.E., Beck A.W., Girard L., Jaber M.R., Barnett C.C. Jr, Brekken R.A. and Fleming J.B. (2005). Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. J. Am. Coll. Surg. 200, 371-377.
38. Huang W., Zhang Y., Varambally S., Chinnaiyan A.M., Banerjee M., Merajver S.D. and Kleer C.G. (2008). Inhibition of CCN6 (Wnt-1- induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. Am. J. Pathol. 172, 893-904.
39. Hurvitz J.R., Suwairi W.M., Van Hul W., El-Shanti H., Superti-Furga A., Roudier J., Holderbaum D., Pauli R.M., Herd J.K., Van Hul E.V., Rezai-Delui H., Legius E., Le Merrer M., Al-Alami J., Bahabri S.A. and Warman M.L. (1999). Mutations in the CCN gene family member WISP3 cause progressive pseudorheumatoid dysplasia. Nat. Genet. 23, 94-98.
40. Ihn H. (2002). The role of TGF-beta signaling in the pathogenesis of fibrosis in scleroderma. Arch. Immunol. Ther. Exp. (Warsz) 50, 325-331.
41. Inadera H., Shimomura A. and Tachibana S. (2009). Effect of Wnt-1 inducible signaling pathway protein-2 (WISP-2/CCN5), a downstream protein of Wnt signaling, on adipocyte differentiation. Biochem. Biophys. Res. Commun. 379, 969-974.
42. Inkson C.A., Ono M., Kuznetsov S.A., Fisher L.W., Robey P.G. and Young M.F. (2008). TGF-beta1 and WISP-1/CCN-4 can regulate each other's activity to cooperatively control osteoblast function. J. Cell. Biochem. 104, 1865-1878.
43. Ivkovic S., Yoon B.S., Popoff S.N., Safadi F.F., Libuda D.E., Stephenson R.C., Daluiski A. and Lyons K.M. (2003). Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 130, 2779-2791.
44. Jiang W.G., Watkins G., Fodstad O., Douglas-Jones A., Mokbel K. and Mansel R.E. (2004). Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr. Relat. Cancer 11, 781-791.
45. Joliot V., Martinerie C., Dambrine G., Plassiart G., Brisac M., Crochet J. and Perbal B. (1992). Proviral rearrangements and overexpression of a new cellular gene (nov) in myeloblastosis-associated virus type 1- induced nephroblastomas. Mol. Cell. Biol. 12, 10-21.
46. Jones J.A., Gray M.R., Oliveira B.E., Koch M. and Castellot J.J. Jr (2007). CCN5 expression in mammals: I. Embryonic and fetal tissues of mouse and human. J. Cell Commun. Signal. 1, 127-143.
47. Juric V., Chen C.C. and Lau L.F. (2009). Fas-mediated apoptosis is regulated by the extracellular matrix protein CCN1 (CYR61) in vitro and in vivo. Mol. Cell. Biol. 29, 3266-3279.
48. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., Guise T.A. and Massague J. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549.
49. Katsube K., Sakamoto K., Tamamura Y. and Yamaguchi A. (2009). Role of CCN, a vertebrate specific gene family, in development. Dev. Growth Differ. 51, 55-67.
50. Katsuki Y., Sakamoto K., Minamizato T., Makino H., Umezawa A., Ikeda M.A., Perbal B., Amagasa T., Yamaguchi A. and Katsube K. (2008). Inhibitory effect of CT domain of CCN3/NOV on proliferation and differentiation of osteogenic mesenchymal stem cells, Kusa-A1. Biochem. Biophys. Res. Commun. 368, 808-814.
51. Kawaki H., Kubota S., Suzuki A., Lazar N., Yamada T., Matsumura T., Ohgawara T., Maeda T., Perbal B., Lyons K.M. and Takigawa M. (2008). Cooperative regulation of chondrocyte differentiation by CCN2 and CCN3 shown by a comprehensive analysis of the CCN family proteins in cartilage. J. Bone Miner. Res. 23, 1751-1764.
52. Kennedy L., Liu S., Shi-Wen X., Chen Y., Eastwood M., Sabetkar M., Carter D.E., Lyons K.M., Black C.M., Abraham D.J. and Leask A. (2007). CCN2 is necessary for the function of mouse embryonic fibroblasts. Exp. Cell Res. 313, 952-964.
53. Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K., Hirohashi S., Inazawa J. and Imoto I. (2007). Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer. Cancer Res. 67, 7095-7105.
54. Kireeva M.L., Lam S.C. and Lau L.F. (1998). Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin alphavbeta3. J. Biol. Chem. 273, 3090-3096.
55. Kleer C.G., Zhang Y., Pan Q. and Merajver S.D. (2004). WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer. Neoplasia 6, 179-185.
56. Kouzu Y., Uzawa K., Kato M., Higo M., Nimura Y., Harada K., Numata T., Seki N., Sato M. and Tanzawa H. (2006). WISP-2 expression in human salivary gland tumors. Int. J. Mol. Med. 17, 567-573.
57. Krishnan V., Bryant H.U. and Macdougald O.A. (2006). Regulation of bone mass by Wnt signaling. J. Clin. Invest. 116, 1202-1209.
58. Kubota S. and Takigawa M. (2007). CCN family proteins and angiogenesis: from embryo to adulthood. Angiogenesis 10, 1-11.
59. Kutz W.E., Gong Y. and Warman M.L. (2005). WISP3, the gene responsible for the human skeletal disease progressive pseudorheumatoid dysplasia, is not essential for skeletal function in mice. Mol. Cell. Biol. 25, 414-421.
60. Lake A.C., Bialik A., Walsh K. and Castellot J.J. Jr (2003). CCN5 is a growth arrest-specific gene that regulates smooth muscle cell proliferation and motility. Am. J. Pathol. 162, 219-231.
61. Lake A.C. and Castellot J.J. Jr (2003). CCN5 modulates the antiproliferative effect of heparin and regulates cell motility in vascular smooth muscle cells. Cell Commun. Signal. 1, 5.
62. Latinkic B.V., Mercurio S., Bennett B., Hirst E.M., Xu Q., Lau L.F., Mohun T.J. and Smith J.C. (2003). Xenopus Cyr61 regulates gastrulation movements and modulates Wnt signalling. Development 130, 2429-2441.
63. Lau L.F. and Lam S.C. (1999). The CCN family of angiogenic regulators: the integrin connection. Exp. Cell Res. 248, 44-57.
64. Leu S.J., Chen N., Chen C.C., Todorovic V., Bai T., Juric V., Liu Y., Yan G., Lam S.C. and Lau L.F. (2004). Targeted mutagenesis of the angiogenic protein CCN1 (CYR61). Selective inactivation of integrin alpha6beta1-heparan sulfate proteoglycan coreceptor-mediated cellular functions. J. Biol. Chem. 279, 44177-44187.
65. Lin C.G., Leu S.J., Chen N., Tebeau C.M., Lin S.X., Yeung C.Y. and Lau L.F. (2003). CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J. Biol. Chem. 278, 24200-24208.
66. Luo J., Chen J., Deng Z.L., Luo X., Song W.X., Sharff K.A., Tang N., Haydon R.C., Luu H.H. and He T.C. (2007). Wnt signaling and human diseases: what are the therapeutic implications? Lab. Invest. 87, 97-103.
67. Luo Q., Kang Q., Si W., Jiang W., Park J.K., Peng Y., Li X., Luu H.H., Luo J., Montag A.G., Haydon R.C. and He T.C. (2004). Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J. Biol. Chem. 279, 55958-55968.
68. Lv H., Fan E., Sun S., Ma X., Zhang X., Han D.M. and Cong Y.S. (2009). Cyr61 is up-regulated in prostate cancer and associated with the p53 gene status. J. Cell. Biochem. 106, 738-744.
69. Maeda A., Nishida T., Aoyama E., Kubota S., Lyons K.M., Kuboki T., Takigawa M. (2009), CCN family 2/connective tissue growth factor modulates BMP signalling as a signal conductor, which action regulates the proliferation and differentiation of chondrocytes. J. Biochem. 145, 207-216.
70. Maillard M., Cadot B., Ball R.Y., Sethia K., Edwards D.R., Perbal B. and Tatoud R. (2001). Differential expression of the ccn3 (nov) protooncogene in human prostate cell lines and tissues. Mol. Pathol. 54, 275-280.
71. Manara M.C., Perbal B., Benini S., Strammiello R., Cerisano V., Perdichizzi S., Serra M., Astolfi A., Bertoni F., Alami J., Yeger H., Picci P. and Scotlandi K. (2002). The expression of ccn3(nov) gene in musculoskeletal tumors. Am. J. Pathol. 160, 849-859.
72. Mason H.R., Grove-Strawser D., Rubin B.S., Nowak R.A. and Castellot J.J. Jr (2004). Estrogen induces CCN5 expression in the rat uterus in vivo. Endocrinology 145, 976-982.
73. Mason H.R., Lake A.C., Wubben J.E., Nowak R.A. and Castellot J.J. Jr (2004). The growth arrest-specific gene CCN5 is deficient in human leiomyomas and inhibits the proliferation and motility of cultured human uterine smooth muscle cells. Mol. Hum. Reprod. 10, 181-187.
74. McCallum L. and Irvine A.E. (2009). CCN3--a key regulator of the hematopoietic compartment. Blood Rev. 23, 79-85.
75. Mercurio S., Latinkic B., Itasaki N., Krumlauf R. and Smith J.C. (2004). Connective-tissue growth factor modulates WNT signalling and interacts with the WNT receptor complex. Development 131, 2137-2147.
76. Miller D.S. and Sen M. (2007). Potential role of WISP3 (CCN6) in regulating the accumulation of reactive oxygen species. Biochem. Biophys. Res. Commun. 355, 156-161.
77. Mo F.E., Muntean A.G., Chen C.C., Stolz D.B., Watkins S.C. and Lau L.F. (2002). CYR61 (CCN1) is essential for placental development and vascular integrity. Mol. Cell. Biol. 22, 8709-8720.
78. Nguyen N., Kuliopulos A., Graham R.A. and Covic L. (2006). Tumorderived Cyr61(CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Cancer Res. 66, 2658-2665.
79. Nguyen T.Q., Roestenberg P., van Nieuwenhoven F.A., Bovenschen N., Li Z., Xu L., Oliver N., Aten J., Joles J.A., Vial C., Brandan E., Lyons K.M. and Goldschmeding R. (2008). CTGF inhibits BMP-7 signaling in diabetic nephropathy. J. Am. Soc. Nephrol. 19, 2098-2107.
80. O'Brien T.P., Yang G.P., Sanders L. and Lau L.F. (1990). Expression of cyr61, a growth factor-inducible immediate-early gene. Mol. Cell. Biol. 10, 3569-3577.
81. Pennica D., Swanson T.A., Welsh J.W., Roy M.A., Lawrence D.A., Lee J., Brush J., Taneyhill L.A., Deuel B., Lew M., Watanabe C., Cohen R.L., Melhem M.F., Finley G.G., Quirke P., Goddard A.D., Hillan K.J., Gurney A.L., Botstein D. and Levine A.J. (1998). WISP genes are members of the connective tissue growth factor family that are upregulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc. Natl. Acad. Sci. USA 95, 14717-14722.
82. Perbal B. (2001). NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol. Pathol. 54, 57-79.
83. Rachfal A.W. and Brigstock D.R. (2005). Structural and functional properties of CCN proteins. Vitam. Horm. 70, 69-103.
84. Rubenstein J., Shen A., Haqq C., Ginziger D., Hyun W., Brigstock D. and Shuman M. (2003). Connective tissue growth factor is expressed in malignant astrocytic tumors and is involved in cell-cycle regulation. Mol. Pathol. 56, 72.
85. Rydziel S., Stadmeyer L., Zanotti S., Durant D., Smerdel-Ramoya A. and Canalis E. (2007). Nephroblastoma overexpressed (Nov) inhibits osteoblastogenesis and causes osteopenia. J. Biol. Chem. 282, 19762-19772.
86. Safadi F.F., Xu J., Smock S.L., Kanaan R.A., Selim A.H., Odgren P.R., Marks S.C. Jr, Owen T.A. and Popoff S.N. (2003). Expression of connective tissue growth factor in bone: its role in osteoblast proliferation and differentiation in vitro and bone formation in vivo. J. Cell. Physiol. 196, 51-62.
87. Schutze N., Kunzi-Rapp K., Wagemanns R., Noth U., Jatzke S. and Jakob F. (2005). Expression, purification, and functional testing of recombinant CYR61/CCN1. Protein Expr. Purif. 42, 219-225.
88. Schutze N., Schenk R., Fiedler J., Mattes T., Jakob F. and Brenner R.E. (2007). CYR61/CCN1 and WISP3/CCN6 are chemoattractive ligands for human multipotent mesenchymal stroma cells. BMC Cell. Biol. 8, 45.
89. Sen M., Cheng Y.H., Goldring B., Lotz M.K. and Carson D.A. (2004). WISP3-dependent regulation of type II collagen and aggrecan production in chondrocytes. Arthritis Rheum. 50, 488-497.
90. Shakunaga T., Ozaki T., Ohara N., Asaumi K., Doi T., Nishida K., Kawai A., Nakanishi T., Takigawa M. and Inoue H. (2000). Expression of connective tissue growth factor in cartilaginous tumors. Cancer 89, 1466-1473.
91. Si W., Kang Q., Luu H.H., Park J.K., Luo Q., Song W.X., Jiang W., Luo X., Li X., Yin H., Montag A.G., Haydon R.C. and He T.C. (2006). CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol. Cell. Biol. 26, 2955-2964.
92. Soon L.L., Yie T.A., Shvarts A., Levine A.J., Su F. and Tchou-Wong K.M. (2003). Overexpression of WISP-1 down-regulated motility and invasion of lung cancer cells through inhibition of Rac activation. J. Biol. Chem. 278, 11465-11470.
93. Su F., Overholtzer M., Besser D. and Levine A.J. (2002). WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. Genes Dev. 16, 46-57.
94. Tanaka S., Sugimachi K., Kameyama T., Maehara S., Shirabe K., Shimada M., Wands J.R. and Maehara Y. (2003). Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma. Hepatology 37, 1122-1129.
95. Tanaka S., Sugimachi K., Saeki H., Kinoshita J., Ohga T., Shimada M., Maehara Y. and Sugimachi K. (2001). A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma. Oncogene 20, 5525-5532.
96. Tang N., Song W.X., Luo J., Haydon R.C. and He T.C. (2008). Osteosarcoma development and stem cell differentiation. Clin. Orthop. Relat. Res. 466, 2114-2130.
97. Thibout H., Martinerie C., Creminon C., Godeau F., Boudou P., Le Bouc Y. and Laurent M. (2003). Characterization of human NOV in biological fluids: an enzyme immunoassay for the quantification of human NOV in sera from patients with diseases of the adrenal gland and of the nervous system. J. Clin. Endocrinol. Metab. 88, 327-336.
98. Thorstensen L., Diep C.B., Meling G.I., Aagesen T.H., Ahrens C.H., Rognum T.O. and Lothe R.A. (2001). WNT1 inducible signaling pathway protein 3, WISP-3, a novel target gene in colorectal carcinomas with microsatellite instability. Gastroenterology 121, 1275-1280.
99. Tsai M.S., Bogart D.F., Castaneda J.M., Li P. and Lupu R. (2002). Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 21, 8178-8185.
100. van Golen K.L., Davies S., Wu Z.F., Wang Y., Bucana C.D., Root H., Chandrasekharappa S., Strawderman M., Ethier S.P. and Merajver S.D. (1999). A novel putative low-affinity insulin-like growth factorbinding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin. Cancer Res. 5, 2511-2519.
101. Vorwerk P., Hohmann B., Oh Y., Rosenfeld R.G. and Shymko R.M. (2002). Binding properties of insulin-like growth factor binding protein-3 (IGFBP-3), IGFBP-3 N- and C-terminal fragments, and structurally related proteins mac25 and connective tissue growth factor measured using a biosensor. Endocrinology 143, 1677-1685.
102. Wang H., Zhang R., Wen S., McCafferty D.M., Beck P.L. and MacNaughton W.K. (2009). Nitric oxide increases Wnt-induced secreted protein-1 (WISP-1/CCN4) expression and function in colitis. J. Mol. Med. 87, 435-445.
103. Woods A., Pala D., Kennedy L., McLean S., Rockel J.S., Wang G., Leask A. and Beier F. (2009). Rac1 signaling regulates CTGF/CCN2 gene expression via TGFbeta/Smad signaling in chondrocytes. Osteoarthritis Cartilage 17, 406-413.
104. Xie D., Yin D., Tong X., O'Kelly J., Mori A., Miller C., Black K., Gui D., Said J.W. and Koeffler H.P. (2004). Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin- TCF/Lef signaling pathways. Cancer Res. 64, 1987-1996.
105. Yanagita T., Kubota S., Kawaki H., Kawata K., Kondo S., Takano-Yamamoto T., Tanaka S. and Takigawa M. (2007). Expression and physiological role of CCN4/Wnt-induced secreted protein 1 mRNA splicing variants in chondrocytes. FEBS J. 274, 1655-1665.
106. Yang Y. and Liao E. (2007). Mutant WISP3 triggers the phenotype shift of articular chondrocytes by promoting sensitivity to IGF-1 hypothesis of spondyloepiphyseal dysplasia tarda with progressive arthropathy (SEDT-PA). Med. Hypotheses 68, 1406-1410.
107. You Z., Saims D., Chen S., Zhang Z., Guttridge D.C., Guan K.L., MacDougald O.A., Brown A.M., Evan G., Kitajewski J. and Wang C.Y. (2002). Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J. Cell Biol. 157, 429-440.
108. Yu Y., Gao Y., Wang H., Huang L., Qin J., Guo R., Song M., Yu S., Chen J., Cui B. and Gao P. (2008). The matrix protein CCN1 (CYR61) promotes proliferation, migration and tube formation of endothelial progenitor cells. Exp. Cell Res. 314, 3198-3208.